Danaher Corporation $DHR Holdings Raised by Csenge Advisory Group

Csenge Advisory Group grew its stake in Danaher Corporation (NYSE:DHR) by 105.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,749 shares of the conglomerate’s stock after acquiring an additional 2,436 shares during the period. Csenge Advisory Group’s holdings in Danaher were worth $1,052,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of DHR. BlackRock Inc. acquired a new stake in shares of Danaher in the second quarter valued at approximately $10,492,520,000. Wellington Management Group LLP increased its position in Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares during the period. Jupiter Topco LLC acquired a new stake in Danaher in the second quarter worth about $1,456,317,000. Generation Investment Management LLP acquired a new stake in Danaher in the second quarter worth about $1,287,949,000. Finally, Bank of America Corp DE bought a new stake in Danaher during the 2nd quarter worth about $993,846,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Price Performance

Shares of DHR opened at $232.08 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.29 and a debt-to-equity ratio of 0.45. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The stock has a market cap of $163.28 billion, a P/E ratio of 28.22, a price-to-earnings-growth ratio of 2.95 and a beta of 0.76. The stock’s 50-day moving average price is $222.11 and its two-hundred day moving average price is $201.53.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts’ consensus estimates of $1.92 by $0.19. The company had revenue of $6.55 billion during the quarter, compared to analysts’ expectations of $6.56 billion. Danaher had a return on equity of 11.17% and a net margin of 16.91%. Danaher’s revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.89 EPS. On average, equities analysts predict that Danaher Corporation will post 8.59 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were issued a dividend of $0.40 per share. The ex-dividend date was Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s payout ratio is currently 26.19%.

Insider Buying and Selling

In other Danaher news, EVP Gregory Milosevich sold 2,100 shares of the company’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at approximately $5,158,277.54. This represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Christopher Bouda sold 7,598 shares of the stock in a transaction on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the completion of the sale, the chief accounting officer owned 9,107 shares in the company, valued at approximately $2,136,137.92. This trade represents a 45.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 10.80% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research reports. Barclays upped their target price on shares of Danaher from $255.00 to $260.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Morgan Stanley lifted their price target on shares of Danaher from $220.00 to $240.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Citigroup lifted their price target on shares of Danaher from $230.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Wall Street Zen raised shares of Danaher from a “hold” rating to a “buy” rating in a research note on Monday, October 26th. Finally, Guggenheim increased their price objective on shares of Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Eighteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $242.91.

Danaher Profile

Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.